Provided By GlobeNewswire
Last update: Feb 14, 2025
SAN DIEGO, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that the Company will participate in the following upcoming investor conferences:
Read more at globenewswire.com1.09
+0.02 (+1.87%)
Find more stocks in the Stock Screener